Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
Document Type
Article
Publication Date
6-1-2019
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abstract
PURPOSE: To develop recommendations for duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer based on the results of trials of 3 months compared with 6 months of treatment.
METHODS: ASCO convened an Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel.
RESULTS: Pooled data from the six International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration randomized controlled trials comprise the evidence base for these guideline recommendations.
RECOMMENDATIONS: The recommendations for therapy duration apply to patients with completely resected stage III colon cancer who are being offered adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine. Recommendations are informed by the findings of a recent pooled analysis of clinical trials that compared 6 months versus 3 months of oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of 6 months. For patients at a low risk of recurrence (T1, T2, or T3 and N1), either 6 months of adjuvant chemotherapy or a shorter duration of 3 months may be offered on the basis of a potential reduction in adverse events and no significant difference in disease-free survival with the 3-month regimen. In determining duration of therapy, the Expert Panel recommends a shared decision-making approach, taking into account patient characteristics, values and preferences, and other factors and including a discussion of the potential for benefit and risks of harm associated with treatment duration. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Clinical Institute
Cancer
Clinical Institute
Digestive Health
Department
Oncology
Department
Gastroenterology
Recommended Citation
Lieu, Christopher; Kennedy, Erin B; Bergsland, Emily; Berlin, Jordan; George, Thomas J; Gill, Sharlene; Gold, Philip J; Hantel, Alex; Jones, Lee; Mahmoud, Najjia; Meyerhardt, Jeffrey; Morris, Arden M; Ruíz-García, Erika; You, Y Nancy; and Baxter, Nancy, "Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline." (2019). Articles, Abstracts, and Reports. 1472.
https://digitalcommons.providence.org/publications/1472
